"10.1371_journal.pone.0106221","plos one","2014-08-29T00:00:00Z","Roger J Bedimo; Henning Drechsler; Mamta Jain; James Cutrell; Song Zhang; Xilong Li; Irfan Farukhi; Rosinda Castanon; Pablo Tebas; Naim M Maalouf","Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Department of Medicine, VA North Texas Health Care System, Dallas, Texas, United States of America; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America; Department of Nuclear Medicine, VA North Texas Health Care System, Dallas, Texas, United States of America; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America","Conceived and designed the experiments: RB. Performed the experiments: RB HD MJ JC RC IF NM. Analyzed the data: RB HD JC SZ XL NM PT. Contributed reagents/materials/analysis tools: RB HD IF NM. Wrote the paper: RB HD PT NM JC.","Roger Bedimo has received research grants from Merck & Co, Janssen Therapeutics, and Bristol Myers Squibb. Heâ€™s also on ad-hoc scientific advisory boards for Janssen Therapeutics, ViiV Health Care, and Bristol Myers Squibb. Pablo Tebas is consultant for Merck & Co. and Gilead, speaker for Janssen Therapeutics and is on the adjudication committee for GSK. This specific study was funded by grants from Merck & Co, and Janssen Therapeutics to the VA North Texas Health Care System for Roger Bedimo. Raltegravir is a drug produced by Merck & Co. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","08","Roger J Bedimo","RJB",10,TRUE,1,7,7,5,TRUE,TRUE,FALSE,0,NA,FALSE
